orbofiban has been researched along with beta-alanine in 1 studies
*beta-Alanine: An amino acid formed in vivo by the degradation of dihydrouracil and carnosine. Since neuronal uptake and neuronal receptor sensitivity to beta-alanine have been demonstrated, the compound may be a false transmitter replacing GAMMA-AMINOBUTYRIC ACID. A rare genetic disorder, hyper-beta-alaninemia, has been reported. [MeSH]
*beta-Alanine: An amino acid formed in vivo by the degradation of dihydrouracil and carnosine. Since neuronal uptake and neuronal receptor sensitivity to beta-alanine have been demonstrated, the compound may be a false transmitter replacing GAMMA-AMINOBUTYRIC ACID. A rare genetic disorder, hyper-beta-alaninemia, has been reported. [MeSH]
| Studies (orbofiban) | Trials (orbofiban) | Recent Studies (post-2010) (orbofiban) | Studies (beta-alanine) | Trials (beta-alanine) | Recent Studies (post-2010) (beta-alanine) |
|---|---|---|---|---|---|
| 48 | 17 | 0 | 3,177 | 207 | 1,807 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asai, F; Naganuma, H; Ogawa, T; Sugidachi, A | 1 |
1 other study(ies) available for orbofiban and beta-alanine
| Article | Year |
|---|---|
Antiplatelet and antithrombotic effects of orbofiban, a new orally active GPIIb/IIIa antagonist, in guinea pigs.
Topics: Adenosine Diphosphate; Administration, Oral; Alanine; Animals; Arteriovenous Shunt, Surgical; Aspirin; beta-Alanine; Bleeding Time; Collagen; Disease Models, Animal; Dose-Response Relationship, Drug; Fibrinolytic Agents; Guinea Pigs; Hemostasis; Hypercholesterolemia; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Thrombosis; Urea | 2000 |